A Study to Assess the Pharmacokinetics, Safety, and Tolerability of Paliperidone Palmitate in Patients With Schizophrenia
Public ClinicalTrials.gov record NCT01559272. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Single-Dose, Open-Label, Randomized, Parallel-Group Study to Assess the Pharmacokinetics, Safety, and Tolerability of a Paliperidone Palmitate 3-Month Formulation in Subjects With Schizophrenia
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The purpose of this study is to assess the pharmacokinetics, safety, and tolerability of a paliperidone palmitate 3-month formulation in patients with schizophrenia.
Study identification
- NCT ID
- NCT01559272
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 1
- Enrollment
- 328 participants
Conditions and interventions
Conditions
Interventions
- Paliperidone IR (Period 1) Drug
- Paliperidone palmitate F015 (Panel A: treatment group 1) Drug
- Paliperidone palmitate F015 (Panel A: treatment group 2) Drug
- Paliperidone palmitate F015 (Panel B: treatment group 1) Drug
- Paliperidone palmitate F015 (Panel B: treatment group 2) Drug
- Paliperidone palmitate F015 (Panel B: treatment group 3) Drug
- Paliperidone palmitate F015 (Panel B: treatment group 4) Drug
- Paliperidone palmitate F015 (Panel B: treatment group 5) Drug
- Paliperidone palmitate F016 Drug
- Paliperidone palmitate F015 (Panel D: treatment group 1) Drug
- Paliperidone palmitate F015 (Panel D: treatment group 2) Drug
- Paliperidone palmitate F015 (Panel D: treatment group 3) Drug
- Paliperidone palmitate F015 (Panel D: treatment group 4) Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years to 65 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Feb 20, 2008
- Primary completion
- Apr 8, 2014
- Completion
- May 23, 2014
- Last update posted
- Sep 17, 2017
2008 – 2014
United States locations
- U.S. sites
- 10
- U.S. states
- 5
- U.S. cities
- 10
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Not listed | Little Rock | Arkansas | — | — |
| Not listed | Cerritos | California | — | — |
| Not listed | Garden Grove | California | — | — |
| Not listed | Glendale | California | — | — |
| Not listed | National City | California | — | — |
| Not listed | Paramount | California | — | — |
| Not listed | Atlanta | Georgia | — | — |
| Not listed | Philadelphia | Pennsylvania | — | — |
| Not listed | Austin | Texas | — | — |
| Not listed | DeSoto | Texas | — | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 26 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT01559272, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Sep 17, 2017 · Synced Sep 2, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT01559272 live on ClinicalTrials.gov.